| Year |
Citation |
Score |
| 2009 |
Meyers RO, Lambert JD, Hajicek N, Pourpak A, Kalaitzis JA, Dorr RT. Synthesis, characterization, and anti-melanoma activity of tetra-O-substituted analogs of nordihydroguaiaretic acid. Bioorganic & Medicinal Chemistry Letters. 19: 4752-5. PMID 19615898 DOI: 10.1016/J.Bmcl.2009.06.063 |
0.593 |
|
| 2008 |
Congdon LM, Pourpak A, Escalante AM, Dorr RT, Landowski TH. Proteasomal inhibition stabilizes topoisomerase IIalpha protein and reverses resistance to the topoisomerase II poison ethonafide (AMP-53, 6-ethoxyazonafide). Biochemical Pharmacology. 75: 883-90. PMID 18062937 DOI: 10.1016/J.Bcp.2007.10.026 |
0.564 |
|
| 2007 |
Pourpak A, Landowski TH, Dorr RT. Ethonafide-induced cytotoxicity is mediated by topoisomerase II inhibition in prostate cancer cells. The Journal of Pharmacology and Experimental Therapeutics. 321: 1109-17. PMID 17351106 DOI: 10.1124/Jpet.106.117457 |
0.616 |
|
| 2007 |
Pourpak A, Dorr RT, Meyers RO, Powell MB, Stratton SP. Cytotoxic activity of Apomine is due to a novel membrane-mediated cytolytic mechanism independent of apoptosis in the A375 human melanoma cell line. Investigational New Drugs. 25: 107-14. PMID 17024575 DOI: 10.1007/S10637-006-9015-6 |
0.596 |
|
| 2006 |
Pourpak A, Meyers RO, Samulitis BK, Sherry Chow HH, Kepler CY, Raymond MA, Hersh E, Dorr RT. Preclinical antitumor activity, pharmacokinetics and pharmacodynamics of imexon in mice. Anti-Cancer Drugs. 17: 1179-84. PMID 17075317 DOI: 10.1097/01.Cad.0000236305.43209.F0 |
0.584 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2017 |
Sun Y, Chao JR, Xu W, Pourpak A, Boyd K, Moshiach S, Qi GY, Fu A, Shao HR, Pounds S, Morris SW. MLF1 is a proapoptotic antagonist of HOP complex-mediated survival. Biochimica Et Biophysica Acta. PMID 28137643 DOI: 10.1016/J.Bbamcr.2017.01.016 |
0.249 |
|
| 2009 |
Lagisetti C, Pourpak A, Goronga T, Jiang Q, Cui X, Hyle J, Lahti JM, Morris SW, Webb TR. Synthetic mRNA splicing modulator compounds with in vivo antitumor activity. Journal of Medicinal Chemistry. 52: 6979-90. PMID 19877647 DOI: 10.1021/jm901215m |
0.246 |
|
| 2008 |
Lagisetti C, Pourpak A, Jiang Q, Cui X, Goronga T, Morris SW, Webb TR. Antitumor compounds based on a natural product consensus pharmacophore. Journal of Medicinal Chemistry. 51: 6220-4. PMID 18788726 DOI: 10.1021/Jm8006195 |
0.23 |
|
| 2007 |
Guo K, Pourpak A, Beetz-Rogers K, Gokhale V, Sun D, Hurley LH. Formation of pseudosymmetrical G-quadruplex and i-motif structures in the proximal promoter region of the RET oncogene. Journal of the American Chemical Society. 129: 10220-8. PMID 17672459 DOI: 10.1021/Ja072185G |
0.214 |
|
| 2011 |
Gundluru MK, Pourpak A, Cui X, Morris SW, Webb TR. Design, synthesis and initial biological evaluation of a novel pladienolide analog scaffold. Medchemcomm. 2: 904-908. PMID 21927710 DOI: 10.1039/C1MD00040C |
0.213 |
|
| 2010 |
Li R, Pourpak A, Morris SW. Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach. Journal of Medicinal Chemistry. 52: 4981-5004. PMID 19610618 DOI: 10.1021/jm9002395 |
0.116 |
|
| 2019 |
Zhang J, Li J, Saucier JB, Feng Y, Jiang Y, Sinson J, McCombs AK, Schmitt ES, Peacock S, Chen S, Dai H, Ge X, Wang G, Shaw CA, Mei H, ... ... Pourpak A, et al. Non-invasive prenatal sequencing for multiple Mendelian monogenic disorders using circulating cell-free fetal DNA. Nature Medicine. PMID 30692697 DOI: 10.1038/s41591-018-0334-x |
0.085 |
|
| 2019 |
Zhang J, Li J, Saucier JB, Feng Y, Jiang Y, Sinson J, McCombs AK, Schmitt ES, Peacock S, Chen S, Dai H, Ge X, Wang G, Shaw CA, Mei H, ... ... Pourpak A, et al. Publisher Correction: Non-invasive prenatal sequencing for multiple Mendelian monogenic disorders using circulating cell-free fetal DNA. Nature Medicine. PMID 30787481 DOI: 10.1038/S41591-019-0391-9 |
0.062 |
|
| Hide low-probability matches. |